文献速递妇科

CDK7是上皮性卵巢癌可靠的预后因素和新的治疗靶点

CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2019-11-24

研究通过免疫组化检测436例卵巢组织(含正常至转移性卵巢肿瘤)中CDK7表达,分析其临床意义;并用CDK7 siRNA或共价CDK7抑制剂THZ1进行体外和体内实验。结果显示CDK7高表达从正常卵巢上皮到上皮性卵巢癌逐渐增加(P < 0.001),与晚期和高级别组织学相关(P = 0.035和P = 0.011),对复发有独立预后意义(P = 0.034);抑制CDK7可降低增殖和迁移、增加凋亡,体内实验显著降低肿瘤重量。结论认为CDK7与侵袭性表型相关,可能是潜在治疗靶点。

要点

  • CDK7高表达从正常卵巢上皮到上皮性卵巢癌逐渐增加(P < 0.001)。
  • CDK7高表达与晚期和高组织学级别相关(P = 0.035和P = 0.011)。
  • CDK7高表达对上皮性卵巢癌复发有独立预后意义(P = 0.034)。

核心结论

  • CDK7与上皮性卵巢癌的侵袭性表型显著相关,并对复发具有独立预后意义。
  • CDK7可能是上皮性卵巢癌患者的潜在治疗靶点,无论铂敏感或耐药。

研究设计与样本

  • 免疫组化检测436例卵巢组织(包括正常至转移性卵巢肿瘤)中CDK7表达并分析临床意义。
  • 体外和体内实验使用CDK7 siRNA或共价CDK7抑制剂THZ1,以阐明CDK7抑制对上皮性卵巢癌细胞肿瘤发生的影响。

主要发现

  • CDK7高表达的患者比例从正常卵巢上皮到上皮性卵巢癌逐渐增加(P < 0.001)。
  • 在上皮性卵巢癌患者中,CDK7高表达与晚期和高组织学级别相关(P = 0.035和P = 0.011)。
  • CDK7高表达对上皮性卵巢癌复发具有独立预后意义(P = 0.034)。
  • siRNA或THZ1抑制CDK7可降低上皮性卵巢癌细胞增殖和迁移、增加凋亡,其抗癌机制由G0/G1细胞周期阻滞引起。
  • 在细胞系异种移植和PDX模型的体内治疗实验中,抑制CDK7显著降低肿瘤重量,该作用由细胞增殖和凋亡介导。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cyclin-dependent kinase 7 (CDK7) engages tumor growth by acting as a direct link between the regulation of transcription and the cell cycle. Here, we investigated the clinical significance of CDK7 expression and its potential as a therapeutic target in epithelial ovarian cancer (EOC). METHODS: CDK7 expression was examined in 436 ovarian tissues including normal to metastatic ovarian tumors using immunohistochemistry, and its clinical implications were analyzed. Furthermore, we performed in vitro and in vivo experiments using CDK7 siRNA or a covalent CDK7 inhibitor (THZ1) to elucidate the effect of CDK7 inhibition on tumorigenesis in EOC cells. RESULTS: The patient incidence of high CDK7 expression (CDK7High) gradually increased from normal ovarian epithelium to EOC (P < 0.001). Moreover, CDK7High was associated with an advanced stage and high-grade histology (P = 0.035 and P = 0.011, respectively) in EOC patients and had an independent prognostic significance in EOC recurrence (P = 0.034). CDK7 inhibition with siRNA or THZ1 decreased cell proliferation and migration, and increased apoptosis in EOC cells, and this anti-cancer mechanism is caused by G0/G1 cell cycle arrest. In in vivo therapeutic experiments using cell-line xenograft and PDX models, CDK7 inhibition significantly decreased the tumor weight, which was mediated by cell proliferation and apoptosis. CONCLUSION: Mechanistic interrogation of CDK7 revealed that it is significantly associated with an aggressive phenotype of EOC, and it has independent prognostic power for EOC recurrence. Furthermore, CDK7 may be a potential therapeutic target for patients with EOC, whether platinum sensitive or resistant.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim J, Cho YJ, Ryu JY, et al. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecol Oncol. 2019. PMID: 31776040. doi:10.1016/j.ygyno.2019.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。